Unger / Steckelings / Souza Dos Santos The Protective Arm of the Renin Angiotensin System (RAS)

Functional Aspects and Therapeutic Implications
1. Auflage 2015
ISBN: 978-0-12-801485-1
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 316 Seiten

The Protective Arm of the Renin Angiotensin System: Functional Aspects and Therapeutic Implications is the first comprehensive publication to signal the protective role of a distinct part of the renin-angiotensin system (RAS), providing readers with early insight into a complex system which will become of major medical importance in the near future. Focusing on recent research, The Protective Arm of the Renin Angiotensin System presents a host of new experimental studies on specific components of the RAS, namely angiotensin AT2 receptors (AT2R), the angiotensin (1-7) peptide with its receptor Mas, and the enzyme ACE 2, which exert significant beneficial, health-promoting actions by counterbalancing the well-known harmful arm of the RAS with its classical angiotensin AT1 receptor. This innovative concept of the protective arm of the RAS, examined in this reference, represents an indispensable background and will be a strong support for biomedical students, researchers, cardiologists, surgeons, nephrologists, diabetologists, and endocrinologists, as well as any other physician or researcher concerned with RAS physiology, pathophysiology and clinical implications. - Provides a complete understanding of the protective side of the Renin Angiotensin System (RAS) involving angiotensin AT2 receptor, ACE2, and Ang(1-7)/Mas receptor - Combines the knowledge of editors who pioneered research on the protective renin angiotensin system including; Dr. Thomas Unger, one of the founders of AT2 receptor research; Dr. Ulrike M. Steckelings, who contributed significantly to first preclinical studies with a novel specific AT2-agonist, and Dr. Robson Santos who pioneered research on angiotensin-(1-7) and its receptor Mas. - Shows that the protective RAS axes are able to ameliorate the course of several cardiovascular, renal, metabolic and neurological diseases - Provides the basis for the understanding of a novel therapeutic approach to stimulate components of the protective arm of the RAS.

Autoren/Hrsg.

Unger, Thomas

Steckelings, U. Muscha

Souza Dos Santos, Robson Augusto

Leseproben

Contributors
Marie-Isabel Aguilar     Department of Biochemistry and Molecular Biology, Monash University, Clayton Victoria 3800, Australia Natalia Alenina Max-Delbrueck-Center for Moleculare Medicine (MDC), Berlin-Buch, Germany Federal University of Minas Gerais, Belo Horizonte, Brazil Instituto Nacional de Ciência e Tecnologia em, NanoBiofarmacêutica (NanoBIOFAR), Belo Horizonte, Brazil Peter W. Angus     Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia Michael Bader Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany Charité Medical Faculty, Berlin, Germany Universidade Federal de Minas Gerais, Belo Horizonte, Brazil Institute for Biology, University of Lübeck, Germany Ana Paula Correa Oliveira Bahia     Departamento de Fisiologia e Biofísica—ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil Dhaniel Baraldi     Department of Pharmacology, Monash University, Clayton Victoria 3800, Australia Lívia Corrêa Barroso     Departamento de Bioquimica e Imunologia, UFMG, Belo Horizonte, Minas Gerais, Brazil Lenice Becker     Sport Center of UFOP, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil Douglas M. Bennion     Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida, USA Serge P. Bottari Laboratory for Fundamental and Applied Bioenergetics, INSERM U1055, Université Grenoble—Alpes Radioanalysis Unit, Institute for Biology and Pathology, CHU de Grenoble, Grenoble, France Peter Buehlmayer     Hangstrasse 18, CH-4144 Arlesheim, Switzerland Maria J. Campagnole-Santos     Department of Physiology and Biophysics, INCT-Nanobiofar, Institute of Biological Sciences, Federal University of Minas Gerais-UFMG, Brazil Robert M. Carey     Department of Medicine, University of Virginia, Charlottesville, Virginia, USA Harshita Chodavarapu     Department of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA Leoluca Criscione     MangiaSano Consulting, Rümelinbachweg 10, CH-4054 Basel, Switzerland Juraj Culman     Institute of Experimental and Clinical Pharmacology, University Hospitals of Schleswig-Holstein, Campus Kiel, Kiel, Germany Björn Dahlöf     Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Gothenburg, Sweden Leon Alexander Danyel     Center for Cardiovascular Research (CCRI), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Germany Marc de Gasparo     Cardiovascular & Metabolic Syndrome Adviser, Rossemaison, Switzerland Mark Del Borgo     Department of Biochemistry and Molecular Biology, Monash University, Clayton Victoria 3800, Australia Kate M. Denton     Department of Physiology, Monash University, Clayton Victoria 3800, Australia Isha S. Dhande     University of Hosuton, Houston, Texas, USA Gere S. diZerega US Biotest, San Luis Obispo Keck School of Medicine, Los Angeles, CA, USA Fernando Pablo Dominici     Department of Biological Chemistry, IQUIFIB, University of Buenos Aires, Buenos Aires, Argentina Adelina M. dos Reis     Department of Physiology & Biophysics, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil Victor J. Dzau     Institute of Medicine of the National Academies, Washington, DC, USA Veronica Valero Esquitino     Center for Cardiovascular Research (CCRI), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Germany Anderson J. Ferreira     Department of Morphology, Federal University of Minas Gerais, Belo Horizonte, MG 31270-901, Brazil Anna Foryst-Ludwig     Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Berlin, Germany Sébastien Foulquier     CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands Rodrigo A. Fraga-Silva     Institute of Bioengineering, Ecole Polytechnique Federale de Lausanne, Lausanne, Vaud, Switzerland Frédéric Frézard     Departamento de Fisiologia e Biofísica—ICB, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil Pascal Furet     Novartis Institute for Biochemical Research, CH-4002 Basel, Switzerland Patricia E. Gallagher     Hypertension and Vascular Research Center, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA Lie Gao     Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA Tracey A. Gaspari     Department of Pharmacology, Monash University, Clayton Victoria 3800, Australia Mariela M. Gironacci     Department of Biological Chemistry, IQUIFIB-CONICET, University of Buenos Aires, Buenos Aires, Argentina Anders Hallberg     Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden Chandana B. Herath     Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia Lucinda M. Hilliard     Department of Physiology, Monash University, Clayton Victoria 3800, Australia Masatsugu Horiuchi     Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Shitsukawa, Ehime, Japan Tahir Hussain     University of Hosuton, Houston, Texas, USA Rebecka Isaksson     Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden Emma S. Jones     Department of Pharmacology, Monash University, Clayton Victoria 3800, Australia Elena Kaschina     Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Berlin, Germany Michael Katovich     Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA Ulrich Kintscher     Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité-Universitätsmedizin Berlin, Berlin, Germany Mats Larhed     Department of Medicinal Chemistry, Division of Organic Pharmaceutical Chemistry, Uppsala University, Uppsala, Sweden Eric Lazartigues     Department of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA Kai Y. Mak     Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia Nephtali Marina     Department of Clinical Pharmacology and Experimental Therapeutics, University College London, London,...